新华制药(00719.HK)A股近日异常波动 早前公布业绩快报及药品中标集采
山东新华制药股份(00719.HK)公布,公司A股在今年1月17日、20日及21日连续三个交易日收盘价格涨幅偏离值累计达到20%。公司指,经核查,近期公司经营情况及内外部经营环境未发生重大变化。经向公司控股股东、实际控制人询问,不存在除已披露事项外的关於公司的应披露而未披露的重大事项,或处於筹划阶段的重大事项。
公司指,今年1月14日公司披露了去年度业绩快报,根据公司财务部门初步测算,去年公司实现归属於上市公司股东的净利润约3亿元人民币,按年增长17.54%。另外今日(21日)公司披露了关於公司格列美(月尿)片、头孢拉定胶囊参与全国药品集中采购中标的公告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.